IRCT20201028049175N10 IRCT 2021-11-16 Arak University of Medical Sciences Effectiveness of Atorvastatin on reducing of death and illness after catheterization Effectiveness of Atorvastatin on mortality and morbidity in catheterization procedures (Permcath) 2021-11-18 anticipated 228 Complete https://irct.ir/trial/59434 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: Sequences web randomization (www.graphpad.com) dual group for creation of simple randomization and closed envelope method with random sequence (SNOSE) for concealment, will be used. Random sequences will be written on the cards and then sequentially put in the envelopes. In order to preserve random sequences, the outer surface of the envelopes are numbered, respectively. Finally, the lid of the envelopes will be pasted and placed inside the boxes, sequentially. At the time of participants registration, one of the envelopes will be open and the allocation group will be revealed, Blinding description: All patients have informed consent to entrance to study, but they do not know about the kind of drugs have been received . The required drugs will be prescribed by the cardiologist, but the person who will analysis the data of patients outcomes will be unaware about the patients group and the kind of received drugs. 3 Complications after permanent catheterization (permcath). Intervention 1: Intervention group: Patients will receive Atorvastatin (Sobhan daru-Iran) 80 mg tablet 4 hours before surgery and 40 mg after surgery for 6 months daily. Intervention 2: Control group: Patients will receive the tablets with a similar shape of Atorvastatin 4 hours before surgery and in concomitant with patients in statin group. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There are no more data.